Current Perspectives in Prostate Cancer Vaccines

被引：2
作者：
Arlen, Philip M. [1 ]
Gulley, James L. [1 ]
机构：
[1] NCI, Tumor Immunol & Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2009年 / 9卷 / 10期
关键词：
Prostate cancer; immunotherapy; vaccine; cancer vaccine; clinical protocols; tumor-associated antigens; COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; ANDROGEN-DEPRIVATION THERAPY; IMMUNE-RESPONSES; CELLULAR IMMUNOTHERAPY; IMMUNOLOGICAL RESPONSE; COMBINATION THERAPY; ANTITUMOR IMMUNITY; RADIATION-THERAPY; CTLA-4; BLOCKADE;
D O I：
10.2174/187152009789735062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The use of vaccines as a potential therapeutic modality for the treatment of cancer has been extensively studied. Recent advances include identification and characterization of tumor-associated antigens, novel vaccine delivery systems, and the combination of vaccines with immune stimulants and other therapeutic modalities. Immunotherapy as a modality for treatment of prostate cancer has received significant attention. There are several characteristics of prostate cancer that make it an ideal target for immunotherapy. Prostate cancer's relative indolence allows sufficient time to generate immune responses, which may take weeks or months to mount. In addition, prostate cancer-associated antigens direct the immune response to prostate cancer cells, thus sparing normal vital tissue. This review focuses on promising new vaccines and novel perspectives in the treatment of prostate cancer.
引用
收藏
页码：1052 / 1057
页数：6
相关论文
共 68 条
[1]  
[Anonymous], 1988, Human Monkeypox
[2]  
[Anonymous], 2008, CELL GENESYS HALTS V
[3]   Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer [J].
Aragon-Ching, Jeanny B. ;
Williams, Kirsten M. ;
Gulley, James L. .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 :4957-4971
[4]   Clinical safety of a viral vector based prostate cancer vaccine strategy [J].
Arlen, Philip M. ;
Skarupa, Lisa ;
Pazdur, Mary ;
Seetharam, Mahesh ;
Tsang, Kwong Y. ;
Grosenbach, Douglas W. ;
Feldman, Jarett ;
Poole, Diane J. ;
Litzinger, Mary ;
Steinberg, Seth M. ;
Jones, Elizabeth ;
Chen, Clara ;
Marte, Jennifer ;
Parnes, Howard ;
Wright, John ;
Dahut, William ;
Schlom, Jeffrey ;
Gulley, James L. .
JOURNAL OF UROLOGY, 2007, 178 (04) :1515-1520
[5]   A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer [J].
Arlen, PM ;
Gulley, JL ;
Parker, C ;
Skarupa, L ;
Pazdur, M ;
Panicali, D ;
Beetham, P ;
Tsang, KY ;
Grosenbach, DW ;
Feldman, J ;
Steinberg, SM ;
Jones, E ;
Chen, C ;
Marte, J ;
Schlom, J ;
Dahut, W .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1260-1269
[6]   Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer [J].
Arlen, PM ;
Gulley, JL ;
Todd, N ;
Lieberman, R ;
Steinberg, SM ;
Morin, S ;
Bastian, A ;
Marte, J ;
Tsang, KY ;
Beetham, P ;
Grosenbach, DW ;
Schlom, J ;
Dahut, W .
JOURNAL OF UROLOGY, 2005, 174 (02) :539-546
[7]   Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer:: A phase 2 trial [J].
Burch, PA ;
Croghan, GA ;
Gastineau, DA ;
Jones, LA ;
Kaur, JS ;
Kylstra, JW ;
Richardson, RL ;
Valone, FH ;
Vuk-Pavlovic, S .
PROSTATE, 2004, 60 (03) :197-204
[8]  
Cavacini LA, 2002, CLIN CANCER RES, V8, P368
[9]  
*CELL TISS GEN THE, 2007, SIP T BRIEF DOC
[10]   Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy [J].
Chakraborty, M ;
Abrams, SI ;
Camphausen, K ;
Liu, KB ;
Scott, T ;
Coleman, CN ;
Hodge, JW .
JOURNAL OF IMMUNOLOGY, 2003, 170 (12) :6338-6347
1234567